

Adverse outcomes and their predictors of dengue fever in pregnancy; a cross sectional study with a follow up

Short title – Dengue in pregnancy

Oshadhi Nallaperuma^{1¶}, Hematha Senanayake^{2¶}, Janaka Godevithana^{3¶}

¹ Department of Obstetrics and Gynaecology, Faculty of Medicine, Sabaragamuwa University of Sri Lanka, Ratnapura, Sri Lanka

² Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka

³ Department of Community Medicine, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka

Corresponding author

Oshadhi Nallaperuma

oshadhinallaperuma@gmail.com (OL)

¶These authors contributed equally to this work.

Abstract

Antenatal dengue infection presents substantial risks to maternal, fetal, and neonatal health, particularly in dengue-endemic regions such as Sri Lanka. This retrospective cross-sectional study with a follow up aimed to investigate the adverse outcomes of antenatal dengue infection and identify predictive parameters associated with maternal, fetal, and neonatal complications. A total of 115 pregnant women with laboratory-confirmed dengue infection admitted to two tertiary referral hospitals in Sri Lanka were followed from admission until delivery and discharge. Data on clinical and laboratory outcome variables were collected and analyzed using descriptive and inferential statistics.

Results revealed a seasonal pattern of dengue infections, with the majority occurring between April and July. Dengue fever (DF) accounted for the majority of cases, followed by dengue hemorrhagic fever (DHF) and dengue expanded syndrome (DES). Maternal adverse outcomes were observed in 27.8% of cases, with predictors including dengue category, trimester of infection, platelet count, and AST levels. Fetal adverse outcomes affected 8.1% of cases, while neonatal adverse outcomes occurred in 28.7% of live births, with transplacental transmission observed in 13.3% of cases.

This study underscores the urgent need for early detection and management of antenatal dengue infection to mitigate adverse outcomes. Identifying predictors of adverse maternal outcomes, such as dengue category and trimester of infection, alongside vigilant monitoring of platelet and AST levels, is crucial for optimizing outcomes. Further research is warranted to develop robust prediction models and refine management strategies for this vulnerable population.

Author summary

This study is diving into how dengue fever affects pregnant women in and how to predict them. Dengue is a huge problem worldwide, with millions of cases each year. Dengue fever is caused by a virus spread by mosquitoes. Being pregnant makes dealing with dengue even harder. Pregnancy brings changes to a woman's body, which can make it tough to spot and treat dengue. We followed up pregnant women with confirmed dengue infections from when they were admitted to the hospital until they had their babies. Our study looked at things like their symptoms, lab results, and any problems they had.

Study found that more than a quarter of the women had serious problems because of dengue. Some even died, or had issues like liver problems or brain swelling. Study found some laboratory markers which could be used to predict these bad outcomes. It's important for doctors to keep an eye on pregnant women with dengue and to act fast if things get serious.

Introduction

The global burden of dengue infections presents a significant public health challenge, with an estimated 100 to 400 million cases occurring annually worldwide, endangering approximately half of the world's population [1]. Within this context, Sri Lanka stands as a notable dengue-endemic country, grappling with an average caseload ranging from 50,000 to 150,000 cases per year [2]. Notably, in 2017, dengue emerged as the leading cause of maternal mortality in Sri Lanka, accentuating the critical importance of understanding and addressing the impact of this vector-borne viral infection during pregnancy [3].

Dengue fever, caused by the dengue virus, presents as a significant health concern with four distinct strains named DEN1 to DEN4. The primary vector responsible for dengue transmission is the *Aedes aegypti* mosquito [4]. Despite the existence of comprehensive guidelines from the World Health Organization (WHO) and local health authorities on the management of dengue, the disease remains a formidable challenge due to its varied clinical manifestations and potential complications [1], [5].

Classification of dengue encompasses three distinct clinical entities: dengue fever (DF), dengue hemorrhagic fever (DHF) with or without shock, and dengue expanded syndrome (DES). Furthermore, the disease progresses through distinct phases, including the febrile phase, critical phase, and recovery phase. In some cases, complications may arise, leading to dengue shock syndrome (DSS), which significantly increases mortality and morbidity rates [5].

Pregnancy accentuates the complexities of managing dengue due to the distinctive physiological changes occurring. Peripheral resistance drops by 40%, while plasma volume increases by 50-60% in the late third trimester. Extracellular volume experiences a 16% rise, accompanied by reductions in packed cell volume and platelet counts, and an increase in white cell count during the peri-partum period [6]. These alterations complicate the diagnosis and management of dengue in pregnancy, given that key features of dengue infection include thrombocytopenia and extracellular fluid loss [1].

While management guidelines for dengue exist, they primarily draw from literature focused on non-pregnant adults and expert opinion [7]. Consequently, there is a critical need to investigate the maternal, fetal, and neonatal outcomes of antenatal dengue infection, along with identifying parameters that may predict adverse outcomes in pregnant individuals. This study aims to address these gaps in knowledge and contribute to the development of evidence-based strategies for the management of antenatal dengue infection.

Methods

This is a cross-sectional study with a follow up conducted over 21 months from 01/01/2017 to 30/09/2018. In this study, the total cohort of pregnant women with laboratory confirmed dengue infection admitted to De Soysa Hospital for Women (DSHW) and National Hospital of Sri Lanka (NHSL), in year 2017 were followed up until delivery and discharge of the mother and the neonate. DSHW, located in Colombo, Sri Lanka, is a tertiary referral women's hospital serving both local patients and referrals from across the country.

In this study, a pregnant woman was defined as a woman carrying an ultrasonically confirmed single viable intra uterine pregnancy. A pregnant woman who developed dengue infection confirmed by either non-structural protein 1 (NS1) antigen or dengue specific immunoglobulin M and G (IgM and IgG) were included in the study. Pregnancies with already identified obstetric or fetal complications were excluded.

Exposure variables were categorized as clinical and laboratory variables. Clinical variables included were characteristic symptoms, number of days on admission, highest recorded temperature during the episode, trimester, and category of dengue (DF, DHF, DES) according to the local guideline [5]. Characteristic symptoms considered in the study were; fever, arthralgia, myalgia, respiratory symptoms, retroorbital pain, headache, back pain, nausea and vomiting. Fever was defined as skin (axillary) temperature $> 37.2^{\circ}\text{C}$ [8]. Trimesters were defined as follows; first trimester (T1) first day of last menstrual period to 13 weeks and 6 days, second trimester (T2) 14 weeks and 0 days to 27 weeks and 6 days, third trimester (T3) 28 weeks and 0 days to delivery [9]. Laboratory variables included were drop of platelet count $<150,000/\mu\text{L}$, lowest platelet count, rise of aspartate aminotransferase (AST) $> 30\text{IU/L}$, highest AST level, rise of alanine aminotransferase (ALT) $>32\text{IU/L}$, and the highest ALT level. Pregnancy specific cut offs were utilized [10].

Several outcome variables were assessed which were sub-categorized as maternal, fetal and neonatal adverse outcomes. Information regarding the possible confounders age and parity were also collected. Age was categorized as <20 , 20-30, 31-40, >40 , and parity as 0, 1-3, >3 . Sample size was not predetermined as the total sample was included in the study.

Identification details of fever related antenatal admissions from 01/01/2017 to 31/12/2017 were gathered from the infection control units of the hospitals and their medical records were

reviewed. Criteria matched cases were selected by the principal investigator and data were extracted in to a preprinted pro forma. These cases were followed until the end of pregnancy and discharge from the hospital. Birth records were accessed from birth suits and delivery data were gathered using identification details. Neonatal records were reviewed if they were admitted separately.

This study was approved by the ethics review committee of Faculty of Medicine, University of Colombo, Sri Lanka (EC-18-024). Informed consent was not taken as all the data were extracted from medical records and none of the personal identifiers were used in the analysis.


Statistical analysis was performed using the SPSS software version 22. Descriptive parameters were presented as mean, median, range and, percentage. Associations between categorical variables were assessed by Chi-square test. However, all continuous variables did not follow a normal distribution. Therefore, independent sample Mann-Whitney U test was used to check the significance of the median difference between two groups; positive for adverse outcomes and negative for adverse outcomes. A P value of <0.05 was considered statistically significant.

Results

During the study period, a total of 326 fever-related admissions were reviewed, from which 115 cases meeting the criteria were selected. Of these, 110 (95.7%) were successfully followed up until delivery, resulting in a loss to follow-up rate of 4.3%. The cases were distributed across the year, with 86 (74.8%) cases occurring between April and July [Figure

1]. Among these cases, there were 73 (63.5%) instances of DF, 39 (33.9%) cases of DHF, and three (2.6%) cases of DES.

Figure 01. Distribution of dengue cases throughout the year



The commonest symptom was fever which was present in 110 (95.7%) patients. Myalgia and headache were the next, being present in 56 (48.7%) and 48 (41.7%) cases respectively. The recorded highest axillary temperature ranged from 37.2 °C to 39.8 °C. The fever had lasted an average of 4.1 days (median 4, range 1-7). Usually, an admission has occurred on day two of fever and the average hospital stay was 5.8 days (median 5, range 2-16). In the DHF category fluid leak had begun on an average of 4.2 days (median 4, range 2-6) after the onset of fever. Platelet counts dropped below 150,000/uL in 59 (80.8%) cases of DF and all cases of DHF, beginning to decline within an average of 2.5 days from fever onset. The lowest recorded platelet counts were 4000/uL in DF and 1000/uL in DHF. Transaminase levels rose in 48 (65.7%) cases of DF and 34 (87.1%) cases of DHF, starting to increase within an average of 3.3 days from fever onset (median 3, range 2-5).

Maternal adverse outcomes

Maternal adverse outcomes were observed in 32 (27.8%) cases, with the remaining 83 (72.2%) cases experiencing no adverse outcomes [Table 1]. Both groups exhibited similar age and parity distributions [Table 2]. Adverse maternal outcomes included one maternal death, two cases of dengue hepatitis, and one case of dengue encephalitis, with the latter three attributed to DES.

Table 01. Summary of adverse outcomes

Adverse outcome	DF	DHF	DES	Total	% *
Maternal					
Maternal death	0	1	0	1	0.86
Intensive care unit admissions	0	19	3	22	19.1
Antepartum hemorrhage	1	0	0	1	0.86
Postpartum hemorrhage	0	3	1	4	3.4
Blood transfusion	1	7	1	9	7.8
Blood product transfusion	0	5	1	6	5.9
Precipitation of labour	7	10	2	19	16.5
Other	0	3	3	6	5.2
Fetal					
First trimester miscarriages	1	1	0	2	1.8
Second trimester miscarriages	0	2	0	2	1.8
Intra uterine deaths	1	2	2	5	4.5
Neonatal					
Meconium stained liquor	5	4	0	9	8.9
Neonatal intensive care unit admissions	8	6	0	14	13.8
Neonatal Dengue	0	2	0	2	1.9
Neonatal death	0	0	0	0	0
Low birth weight	10	3	0	13	12.8
Live births	67	34	1	101	100

*The total number of cases in maternal, fetal and neonatal category were, 115, 110 & 101 respectively.

(DF – dengue fever, DHF – dengue hemorrhagic fever, DES- dengue expanded syndrome)

Table 02. Distribution of confounders

	Positive for adverse outcomes		Negative for adverse outcomes		P value
For maternal adverse outcomes					
Maternal characteristic	n= 32	%	n= 83	%	
Age					

<20	0	0	7	8.43	.744
20-30	19	59.37	51	61.44	
31-40	12	37.5	23	27.71	
>40	1	3.12	2	2.4	
Parity					
0	12	37.5	37	44.57	.783
1-3	19	59.37	44	53.01	
>3	1	3.12	2	2.4	
For fetal and neonatal adverse outcomes					
Maternal characteristic	n= 38	%	n= 72	%	
Age					
<20	0	0	6	8.33	.522
20-30	25	65.78	43	59.72	
31-40	10	26.31	23	31.94	
>40	3	7.89	0	0	
Parity					
0	16	42.1	30	41.66	.890
1-3	22	57.89	39	54.16	
>3	0	0	3	4.16	

Maternal death occurred due to delayed presentation with DSS in a 27-year-old female at a gestation of 19 weeks and five days. A history of fever was elicited. Dengue IgM and IgG tests were positive. A platelet count of 8000/uL and elevated transaminases (AST 11840 IU/L, ALT 1850 IU/L) were noted. patient experienced cardiorespiratory arrest on admission, leading to death on the same day after miscarrying the baby.

A case of dengue encephalitis presented with generalized tonic-clonic convulsions and tested positive for NS1 antigen, dengue IgM, and IgG in blood and cerebrospinal fluid. Following a slow recovery over two weeks, the patient had an uneventful antenatal period and delivered a healthy baby. The two cases of dengue hepatitis developed fulminant hepatic failure, with one progressing to hepatic encephalopathy [Table 3].

Table 3. Two cases of dengue hepatitis

	Case 01	Case 02
Age (in years)	20	23
Gestation on admission	26 weeks	32 weeks and 1 day
Dengue category	DES	DES
NS1	Positive	Positive
Dengue IgM	Positive	Positive
Dengue IgG	Positive	Positive
Fluid leakage developed on	Day 04	Day 04
Lowest platelet count	13,000/uL (recorded on day 6)	6,000/uL (recorded on day 7)
Highest AST	9670 IU/L	6644 IU/L
Highest ALT	3018 IU/L	2011 IU/L
Fetal outcome	IUD	IUD
Gestation at IUD	26 weeks and 2 days	32 weeks and 5 days
Maternal complications	Fulminant hepatic failure	Hepatic encephalopathy
	Profound coagulopathy	PPH necessitating balloon tamponade, and blood transfusion
ICU admission	13 days	11 days

(IUD – intra uterine death, DES – dengue expanded syndrome, ICU – intensive care unit, PPH -post-partum haemorrhage, AST- aspartate amino transferase, ALT-alanine amino transferase)

Intensive care unit (ICU) admission was primarily due to the development of DHF. Among the three cases of post-partum hemorrhage (PPH) in the DHF category, one experienced massive blood loss necessitating insertion of a balloon tamponade and transfusion of six units of red cell concentrates and other blood products, with a platelet count of 39,000/uL during delivery. Labor precipitation during or immediately following the dengue episode in the third

trimester showed a significant association with dengue category ($P = .013$). Other maternal complications in the DHF category included intrapartum maternal bradycardia, ventricular bigeminy, and bleeding manifestations such as hemoptysis and hematuria.

Predictors of maternal adverse outcomes

The predictors of maternal adverse outcome were assessed by comparing variables between the two groups; positive for maternal adverse outcome and negative for maternal adverse outcomes. Among categorical variables, (1) category of dengue, (2) trimester of which it developed predicted the maternal adverse outcomes with a statistically significant difference ($P < .001$, $P = .028$). Presence of headache, nausea and vomiting showed an inverse relationship in the chi-squared test [Table 4]. Of continuous variables, a lower platelet count and higher AST level were associated with adverse maternal outcomes ($P < .001$, $P = .01$). However, none of the other variables was associated with adverse maternal outcomes [Table 5].

Table 04. Predictors of adverse outcomes – categorical variables

	Maternal					Fetal and neonatal				
	Positive for adverse outcomes		Negative for adverse outcomes		P value	Positive for adverse outcomes		Negative for adverse outcomes		P value
Predictor variable	n=	%	n=	%		n=	%	n=	%	
Category of dengue										
DF	8	10.9	65	89	< 0.001	20	28.9	49	71	.194
DHF	21	53.8	18	46.1		16	42.1	22	57.8	
DES	3	100	0	0		2	66.6	1	33.3	
Trimester										
First trimester	0	0	23	100	.028	7	33.3	14	66.6	.671
Second trimester	11	23.9	35	76		13	30.2	30	69.7	
Third trimester	21	45.6	25	54.3		18	39.1	28	60.8	
Clinical										
Days on admission > 2	8	30.7	18	69.2	.703	9	37.5	15	62.5	.730

Predictor variable	Median - Positive for adverse outcomes	Median -Negative for adverse outcomes	p-value
Maternal			
Highest temperature	38.5	38.7	1.0
Lowest platelet count	37.0	87.0	<0.001
Highest AST	92.0	50.0	0.01
Highest ALT	52.0	34.0	0.34
Fetal and neonatal			
Highest temperature	38.9	38.6	0.60
Lowest platelet count	65.5	69.5	0.53
Highest AST	69.5	57.0	0.20
Highest ALT	38.0	35.5	0.40

Days on admission ≤ 2	24	26.9	65	73		29	33.7	57	66.2	
Fever lasted > 4 days	11	26.1	31	73.8	.974	14	35	26	65	.652
Fever lasted ≤ 4 days	18	26.4	50	73.5		20	30.7	45	69.2	
Highest T > 38 °C)	23	25.8	66	74.1	.379	28	32.5	58	67.4	.406
Highest T ≤ 38 °C)	9	34.6	17	65.3		10	41.6	14	58.3	
Headache	6	12.5	42	87.5	.001	13	27.6	34	72.3	.189
Myalgia	16	29.6	38	70.3	.684	18	33.9	35	66	.901
Arthralgia	15	27.2	40	72.7	.899	18	33.9	35	66	.901
Respiratory symptoms	7	38.8	11	61.1	.254	6	33.3	12	66.6	.905
Retroorbital pain	2	15.3	11	84.6	.287	3	25	9	75	.461
Nuasea and vomiting	4	12.9	27	87	.030	11	36.6	19	63.3	.774
Backpain	9	33.3	18	66.6	.465	10	38.4	16	61.5	.630

(T – temperature, DF – dengue fever, DHF – dengue hemorrhagic fever, DES- dengue expanded syndrome)

Table 05. Predictors of adverse outcomes – continuous variables

(AST- aspartate amino transferase, ALT-alanine amino transferase)

Fetal adverse outcomes

The risk of fetal adverse outcomes, excluding cases lost to follow-up, was 8.1% (9/110)

[Table 1]. Five cases of intrauterine fetal demise (IUD) were reported, with two associated

with dengue hepatitis, two with DHF, and one with DF [Table 6]. Additionally, two second-trimester miscarriages occurred, one coinciding with maternal death and the other with DHF at 14 weeks' gestation.

Table 06. Summary of intra-uterine deaths

	Case 03	Case 04	Case 05
Maternal age (in years)	21	29	28
Period of gestation on admission	27 weeks and 2 days	36 weeks and 1 day	38 weeks
Dengue category	DF	DHF	DHF
NS1	Positive	Positive	Positive
Dengue IgM	Not available	Not available	Not available
Dengue IgG	Not available	Not available	Not available
Fluid leakage developed on	None	Day 05	Day 05
Least platelet count	56,000/uL	8,000/uL	85,000/uL
Highest AST	485 IU/L	749 IU/L	20 IU/L
Highest ALT	367 IU/L	996 IU/L	24 IU/L
Fetal outcome	IUD	IUD	IUD
Gestation at IUD	28 weeks and 3 days	38 weeks	38 weeks and 4 days
Maternal complications	None	None	None

(DF – dengue fever, DHF – dengue hemorrhagic fever, DES- dengue expanded syndrome, IUD – Intra uterine death, AST- aspartate amino transferase, ALT-alanine amino transferase)

Neonatal adverse outcomes

There were 29 cases with neonatal adverse outcomes for 101 live births (28.7%) [Table 1].

Reasons for neonatal intensive care unit admissions were for respiratory support in 10 cases,

neonatal dengue in two cases, mother being in ICU in one case. The risk of transplacental transmission of dengue was 13.3% (2/15) when a live birth occurred during the dengue episode. One neonatal dengue infection occurred when the mother developed DHF at 40 weeks' gestation, and the baby was delivered while the mother was still febrile, with the neonate exhibiting thrombocytopenia and testing positive for NS1 antigen, IgM, and IgG, but recovering without sequelae. The other neonatal dengue infection occurred when the mother developed DHF at 37 weeks and 3 days' gestation, with the baby born at 38 weeks testing positive for NS1 antigen on the third day but not developing overt dengue infection, and subsequently being discharged healthy.

Owing to the small numbers, fetal and neonatal adverse outcomes were pooled together for the analysis of predictors. Two groups were divided as positive and negative to have either fetal or neonatal outcome. Age and parity had a similar distribution in both groups [Table 02]. None of the categorical or continuous variables showed a significant association with fetal or neonatal outcomes [Table 4, 5].

Discussion

The findings of this study shed light on the multifaceted challenges posed by antenatal dengue infection, particularly in regions endemic to the disease like Sri Lanka. Dengue infections exhibit a distinct seasonal pattern, with the majority of cases occurring during the monsoon months from April to July. This underscores the importance of implementing robust vector control measures to mitigate the spread of the disease, especially during peak transmission periods.

Maternal adverse outcomes emerged as a significant concern, affecting over a quarter of the cases studied. These outcomes ranged from maternal death to complications such as dengue hepatitis and encephalitis. The presence of DHF emerged as a prominent risk factor for ICU admissions and severe postpartum hemorrhage (PPH), further emphasizing the severity of dengue-related complications in pregnant women.

The maternal mortality ratio (1/101) in the study differed significantly from the general population ratio for the index year which is 39 per 100,000 live births ($P < .001$) [3]. In the case of the maternal death in this series, it is important to note the delay in presentation was a significant reason for the adverse outcome. This underscores the urgent need for prompt detection and intervention strategies to prevent fatalities associated with dengue infection during pregnancy. Following a national recommendation to admit pregnant women with fever to hospitals after 2019 has aimed to capture dengue fever cases more effectively [7].

Most literature on this topic consists of case series in Sri Lanka, with one prospective study focusing on 15 cases of dengue fever in pregnancy, revealing secondary infection (both IgM and IgG positive) to be more common than primary infection (only IgM positive) [11], [12]. However, IgM and IgG assessments were lacking in the majority of cases in our study, limiting confirmation of this finding. Association of adverse outcomes with secondary dengue infection was validated in vivo using a mouse model [13]. Notably, our study traced nearly all possible dengue infection cases in two premier Sri Lankan hospitals, with a low 4.3% loss to follow-up rate.

A semi-ecological study in French Guiana associated dengue infection in the first trimester with post-partum hemorrhage (PPH) and preterm birth [14]. However, none of the first-

trimester episodes in our study were linked to maternal adverse outcomes, while precipitation of labor occurred in the third trimester, significantly associated with DHF compared to DF. Postpartum hemorrhage risk was low at 3.4%, with a 7.8% risk of needing a blood transfusion, consistent with previous studies [15].

Predictive parameters associated with adverse maternal outcomes were identified, including dengue category, trimester of infection, and specific laboratory markers such as platelet count and AST levels. Lower platelet counts and elevated AST levels were particularly indicative of adverse outcomes, highlighting the potential utility of these parameters as early warning signs for healthcare providers managing antenatal dengue cases. This is a novel finding in our study. However, presence of headache, nausea and vomiting were negatively associated with maternal adverse outcomes. This may be due to the small sample size or retrospective nature of data collection. If a patient is severely ill on presentation, they may not have expressed these symptoms or may not have documented as the diagnosis was obvious.

Our study reported a significant difference in intrauterine fetal demise (IUD) rates compared to national statistics, with similar findings to a prospective matched study [3], [16]. The risk of adverse fetal outcomes, including intrauterine demise (IUD) and miscarriages, underscores the potential impact of maternal dengue infection on fetal health and viability. Restrepo et al demonstrated a significant association between low birth weight and antenatal dengue infection in a retrospective cohort study [17]. In contrast, risk of having a low birth weight (<2.5kg) was 12.8% (13/101) in the index study and it is not statistically different (P=.499) from the national value of 15.7% for the same year [3].

Transplacental transmission of dengue infection was observed in a subset of cases, displaying the potential for vertical transmission and the need for close monitoring of neonates born to dengue-infected mothers. Mother-to-child transmission of dengue fever is well established in literature [18]-[20]. While the percentage of cases with transplacental transmission was relatively low, the implications for neonatal health warrant further investigation, particularly regarding long-term sequelae and management strategies. Clinical or laboratory variables did not show promising predictability for fetal or neonatal adverse outcomes, possibly due to the time gap from infection to delivery and small numbers precluding subgroup analysis. This highlights the complexity of dengue infection during pregnancy and emphasizes the need for further research to exemplify the underlying mechanisms and risk factors associated with adverse fetal and neonatal outcomes.

Limitations of this study include its retrospective design and potential underreporting of clinical variables. The lack of consistent documentation regarding the method of gestational age estimation further complicates the interpretation of findings related to trimester-specific outcomes. Additionally, the small sample size may limit the generalizability of the results, warranting further investigation in larger, prospective studies.

In conclusion, antenatal dengue infection poses significant risks to maternal, fetal, and neonatal health, necessitating timely detection and intervention strategies to mitigate adverse outcomes. The identification of predictive parameters for adverse maternal outcomes provides valuable insights for healthcare providers managing dengue-infected pregnant women. However, further research is needed to elucidate the complex interplay of factors influencing fetal and neonatal outcomes and to develop targeted management strategies to optimize pregnancy outcomes in the context of dengue infection.

This study was funded by the research team and there are no conflicts of interest to declare.

Reference

1. World Health Organization [internet]. Dengue guidelines for diagnosis, treatment, prevention and control: new edition; 2009. [cited 2024 Feb 20]
Available from: <https://apps.who.int/iris/handle/10665/44188>
2. Sri Lanka Epidemiology Unit [internet]. Trends; 2020. [cited 2024 Feb 20] Available from:
https://www.epid.gov.lk/web/index.php?option=com_casesanddeaths§ion=trends&Itemid=448&lang=en
3. Family Health Bureau [internet]. Annual Report; 2017. [cited 2024 Feb 20] Available from:
<https://fhb.health.gov.lk/annual-report/>
4. World Health Organization [internet]. Dengue fever – Sri Lanka; 2017. [cited 2024 Feb 20]
Available from: <https://www.who.int/emergencies/disease-outbreak-news/item/19-july-2017-dengue-sri-lanka-en>
5. Sri Lanka Epidemiology Unit [internet]. Guidelines on management of DF/DHF in adults; 2012. [cited 2024 Feb 20] Available from:
https://www.dengue.health.gov.lk/web/images/Guidelines_on_management_of_dengue_fever_and_dengue_haemorrhagic_fever_in_adults_1.pdf
6. Pipkin FB. Maternal physiology. In: Edmonds DK, Lees C, Bourne T, editors. Dewhurst's text book of Obstetrics and Gynaecology. New Jersey: Wiley-Blackwell; 2018. p.1-17
7. Sri Lanka Medical Association: National Guidelines Clinical management of dengue infection in pregnancy; 2019. [cited 2024 Feb 20] Available from:
https://slma.lk/wp-content/uploads/2019/11/National-Guidelines-on-Clinical-Management-of-Dengue-Infection-in-Pregnancy-Reprint-version_new.pdf

8. Jameson L, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison's Principles of Internal Medicine. 20th ed. New York: McGraw-Hill; 2018.
9. American College of Obstetricians and Gynecologists [internet]. How Your Fetus Grows During Pregnancy; 2024. [cited 2024 Feb 20] Available from: <https://www.acog.org/womens-health/faqs/how-your-fetus-grows-during-pregnancy>
10. Nelson-Piercy C. Handbook of Obstetric Medicine. 6th ed. Florida: CRC Press; 2001.
11. Kariyawasam S, Senanayake H. Dengue infections during pregnancy: case series from a tertiary care hospital in Sri Lanka. *J Infect Dev Ctries* 2010;24:767–5.
12. Waduge R, Malavige GN, Pradeepan M, Wijeyaratne CN, Fernando S, Seneviratne SL. Dengue infections during pregnancy: a case series from Sri Lanka and review of the literature. *J Clin Virol Off Publ Pan Am Soc Clin Virol* 2006;37:27–33.
13. Ng JKW, Zhang SL, Tan HC, Yan B, Maria Martinez Gomez J, Tan WY, et al. First Experimental In Vivo Model of Enhanced Dengue Disease Severity through Maternally Acquired Heterotypic Dengue Antibodies. *PLoS Pathog* 2014;10(4): e1004031.
14. Hanf M, Friedman E, Basurko C, Roger A, Bruncher P, Dussart P et al. Dengue epidemics and adverse obstetrical outcomes in French Guiana: a semi-ecological study. *Trop Med Int Health*. 2014;19:153-8.
15. Carles G, Talarmin A, Peneau C, Bertsch M. Dengue fever and pregnancy: A study of 38 cases in french Guiana. *J Gynecol Obstet Biol Reprod (Paris)* 2000;29:758–2.
16. Basurko C, Everhard S, Matheus S, Restrepo M, Hildéral H, Lambert V. et at. A prospective matched study on symptomatic dengue in pregnancy. *PLoS ONE* 2018;13(10): e0202005.
17. Restrepo BN, Isaza DM, Salazar CL, Ramírez JL, Upegui GE, Ospina M. Prenatal and postnatal effects of dengue infection during pregnancy. *Biomed Rev Inst Nac Salud* 2003;23:416–3.

18. Tan PC, Rajasingam G, Devi S, Omar SZ. Dengue infection in pregnancy: prevalence, vertical transmission, and pregnancy outcome. *Obstet Gynecol* 2008;111:1111–7.
19. Phongsamart W, Yoksan S, Vanaprapa N, Chokephaibulkit K. Dengue virus infection in late pregnancy and transmission to the infants. *Pediatr Infect Dis J* 2008;27:500–4.
20. Basurko C, Carles G, Youssef M, Guindi WEL. Maternal and fetal consequences of dengue fever during pregnancy. *Eur J Obstet Gynecol Reprod Biol* 2009;147:29–2.

Supporting Information

- S1. Dengue data set